CN110650733A - 经过修饰的aav衣壳和其用途 - Google Patents

经过修饰的aav衣壳和其用途 Download PDF

Info

Publication number
CN110650733A
CN110650733A CN201880025324.7A CN201880025324A CN110650733A CN 110650733 A CN110650733 A CN 110650733A CN 201880025324 A CN201880025324 A CN 201880025324A CN 110650733 A CN110650733 A CN 110650733A
Authority
CN
China
Prior art keywords
aav
capsid protein
amino acid
viral vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880025324.7A
Other languages
English (en)
Chinese (zh)
Inventor
安娜希塔·喀拉瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Dev Ram Biotechnology Ltd By Share Ltd
Original Assignee
A Dev Ram Biotechnology Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Dev Ram Biotechnology Ltd By Share Ltd filed Critical A Dev Ram Biotechnology Ltd By Share Ltd
Publication of CN110650733A publication Critical patent/CN110650733A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201880025324.7A 2017-02-28 2018-02-28 经过修饰的aav衣壳和其用途 Pending CN110650733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762464878P 2017-02-28 2017-02-28
US62/464,878 2017-02-28
PCT/US2018/020215 WO2018160686A1 (en) 2017-02-28 2018-02-28 Modified aav capsids and uses thereof

Publications (1)

Publication Number Publication Date
CN110650733A true CN110650733A (zh) 2020-01-03

Family

ID=63370228

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880025324.7A Pending CN110650733A (zh) 2017-02-28 2018-02-28 经过修饰的aav衣壳和其用途

Country Status (7)

Country Link
US (1) US20210130413A1 (https=)
EP (1) EP3589277A4 (https=)
JP (1) JP2020510424A (https=)
CN (1) CN110650733A (https=)
AU (1) AU2018227483A1 (https=)
CA (1) CA3054687A1 (https=)
WO (1) WO2018160686A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113121652A (zh) * 2021-04-19 2021-07-16 上海信致医药科技有限公司 视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用
CN113564187A (zh) * 2021-07-30 2021-10-29 上海信致医药科技有限公司 基于aav的抗血管生成基因递送系统及其用途
CN114340683A (zh) * 2019-04-15 2022-04-12 衣阿华大学研究基金会 用于转基因表达的方法和组合物
CN116096377A (zh) * 2020-05-05 2023-05-09 杜克大学 跨物种相容的腺相关病毒组合物及其使用方法
CN116121274A (zh) * 2020-07-29 2023-05-16 北京三诺佳邑生物技术有限责任公司 一组肝靶向新型腺相关病毒的获得及其应用
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
WO2025246365A3 (en) * 2025-06-20 2026-04-16 Hangzhou Jiayin Biotech Ltd. Aav variants and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CN110546257B (zh) 2017-03-17 2024-03-01 阿德夫拉姆生物技术股份有限公司 用于增强基因表达的组合物和方法
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
WO2020068990A1 (en) * 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
TW202102526A (zh) * 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
TW202532428A (zh) * 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
BR112023003548A2 (pt) * 2020-09-03 2023-04-04 Univ Massachusetts Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo
CN116528892A (zh) * 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
TW202242124A (zh) * 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
CN114686448A (zh) * 2022-03-31 2022-07-01 上海勉亦生物科技有限公司 具有肝脏特异靶向性的纯化的腺相关病毒及其应用
CN112961220B (zh) * 2021-04-19 2023-11-17 信念医药科技(上海)有限公司 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体
MX2023014041A (es) 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
CN117230117A (zh) * 2023-08-04 2023-12-15 中国科学院深圳先进技术研究院 重组腺相关病毒包装质粒、突变体及其制备方法和应用
CN117143920A (zh) * 2023-08-30 2023-12-01 呈诺再生医学科技(北京)有限公司 一种治疗新生血管性眼部疾病的基因药物
CN117368466B (zh) * 2023-12-08 2024-03-12 安徽惠邦生物工程有限公司 用生化分析仪测定尿结合珠蛋白的试剂盒及其制备方法
WO2025214359A1 (en) * 2024-04-09 2025-10-16 Hangzhou Jiayin Biotech Ltd. A novel aav variant
GB202414499D0 (en) 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103561774A (zh) * 2011-04-22 2014-02-05 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2015138616A1 (en) * 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
US20170044504A1 (en) * 2010-10-06 2017-02-16 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN106456711A (zh) * 2014-02-25 2017-02-22 曼彻斯特大学 使用基因疗法治疗视网膜退化

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349838C (en) * 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044504A1 (en) * 2010-10-06 2017-02-16 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103561774A (zh) * 2011-04-22 2014-02-05 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
CN106456711A (zh) * 2014-02-25 2017-02-22 曼彻斯特大学 使用基因疗法治疗视网膜退化
WO2015138616A1 (en) * 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNAHITA KERAVALA ET AL.: "Assessment of next-generation AAV variants in gerbil and non-human primate retina following intravitreal injection", 《ARVO ANNUAL》 *
HAIFENG CHEN: "Adeno-associated virus vectors for human gene therapy", 《WORLD JOURNAL OF MEDICAL GENETICS》 *
HANEN KHABOU ET AL.: "Insight Into the Mechanisms of Enhanced Retinal Transduction by the Engineered AAV2 Capsid Variant-7m8", 《BIOTECHNOLOGY AND BIOENGINEERING》 *
RYAN R.KLIMCZAK ET AL.: "A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Muller Cells", 《PLOS ONE》 *
宋清露: "遗传性视网膜变性基因治疗临床试验研究现状与进展", 《中华眼底病杂志》 *
杨仁池等: "《血友病》", 31 January 2017, 上海科学技术出版社 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
CN114340683A (zh) * 2019-04-15 2022-04-12 衣阿华大学研究基金会 用于转基因表达的方法和组合物
CN116096377A (zh) * 2020-05-05 2023-05-09 杜克大学 跨物种相容的腺相关病毒组合物及其使用方法
US12577586B2 (en) 2020-05-05 2026-03-17 Duke University Cross-species compatible adeno-associated virus compositions and methods of use thereof
CN116121274A (zh) * 2020-07-29 2023-05-16 北京三诺佳邑生物技术有限责任公司 一组肝靶向新型腺相关病毒的获得及其应用
CN113121652A (zh) * 2021-04-19 2021-07-16 上海信致医药科技有限公司 视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用
CN113121652B (zh) * 2021-04-19 2022-10-11 上海信致医药科技有限公司 视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用
CN113564187A (zh) * 2021-07-30 2021-10-29 上海信致医药科技有限公司 基于aav的抗血管生成基因递送系统及其用途
WO2025246365A3 (en) * 2025-06-20 2026-04-16 Hangzhou Jiayin Biotech Ltd. Aav variants and uses thereof

Also Published As

Publication number Publication date
US20210130413A1 (en) 2021-05-06
WO2018160686A1 (en) 2018-09-07
EP3589277A4 (en) 2020-08-26
JP2020510424A (ja) 2020-04-09
CA3054687A1 (en) 2018-09-07
EP3589277A1 (en) 2020-01-08
AU2018227483A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
CN110650733A (zh) 经过修饰的aav衣壳和其用途
US12030914B2 (en) Modified AAV capsids and uses thereof
US11766487B2 (en) Treatments for retinal disease
EP3717636B1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
EP3448437B1 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
JP7623703B2 (ja) 硝子体内送達のためのバリアントａａｖキャプシド
TW202313096A (zh) 衣殼變異的重組腺相關病毒及其應用
US20240335560A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN117736274A (zh) 一种腺相关病毒衣壳蛋白及其用途
HK40077196A (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
CN118146317A (zh) 一种腺相关病毒衣壳蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20230825